10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM)

Recombinant Antibody
Catalog # APR11034

Specification

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Product Information

Application	**FC, Kinetics, Animal Model**
Primary Accession	P20273
Reactivity	**Human**
Clonality	**Monoclonal**
Isotype	**IgG1**
Calculated MW	**146.48 KDa**

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Additional Information

Target/Specificity
Siglec-2 / CD22

Endotoxin
< 0.001EU/ μg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Protein Information

Name CD22 {ECO:0000303|PubMed:1691828, ECO:0000312|HGNC:HGNC:1643}

Function
Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:34330755, PubMed:8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the

negative regulation of BCR signaling (PubMed:8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:20516366).

Cellular Location
Cell membrane; Single-pass type I membrane protein

Tissue Location
B-lymphocytes.

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) - Images



Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-CLM)is more than 96.81% ,determined by SEC-HPLC.